SAN DIEGO--(BUSINESS WIRE)--Kurin Inc., manufacturer of Kurin® blood culture collection sets, responds to comments made by Greg Bullington, CEO of Magnolia Medical, in a letter Magnolia published regarding their patent-infringement lawsuit against Kurin.
“Magnolia’s unusual tactic to email blast their allegations of patent infringement has created confusion for healthcare providers, and we are compelled to address this action,” said Bob Rogers, CEO of Kurin and inventor of the Kurin Lock®. “Kurin reassures our customers and potential customers that these allegations are false. Kurin is here solely to serve our customers, and we will continue to do so with disruptive technological innovations like the elegantly simple, FDA 510(k) cleared, Kurin Lock. In contrast, Magnolia Medical could be a study on mismanagement. Steripath has been on the market for years, but its poor design makes it bulky, awkward, and difficult to operate. Their response to address these product deficiencies was to launch virtually the same device: Steripath Gen. 2.”
Continuing, Rogers said, “Magnolia has engaged in a pattern of deception, marketing a device it claims does not require FDA 510(k) clearance (Kurin has been issued two 510(k) clearances), and misleading customers with selective use of clinical performance data. Since we launched the Kurin Lock, Magnolia has continuously told customers that Kurin does not work. Magnolia, now desperate, really wants everyone to believe that they invented the Kurin Lock! If this were true, Magnolia would never have chosen its Rube Goldberg Steripath design.
“When you compare the two devices it is clear, the Kurin Lock is unrelated to anything Magnolia ever conceived. In fact, the U.S. Patent Office has repeatedly found the design of the Kurin Lock to be novel compared to Magnolia’s patents, and has already issued three patents on the Kurin Lock concept,” said Mr. Rogers. “The Kurin Lock does not infringe any Magnolia patent and we are confident that this position will be proven in court.
“In closing,” said Rogers, “we are quite familiar with this situation. At our last company, Ivera Medical, makers of the green Curos Port Protector, we prevailed over a host of similar patent related attacks. As with Curos, the Kurin Lock is, and will remain, on the market throughout this process, as long as it takes.”
About Kurin, Inc.
Kurin Inc., a certified Minority Business Enterprise (MBE), is focused on the design, development, manufacture, marketing, and sale of products that help healthcare providers reduce contaminated blood cultures. San Diego-based Kurin has received FDA 510(k) market clearance. For more information, visit the website at www.kurin.com.